Skip to content

A study to compare the dose requirement of Oxytocin for management of failure of uterus to contract during caeserean delivery, in patients who received prophylactic Phenylephrine (which is given to manage fall in blood pressure following spinal anaesthesia)

A Randomized Controlled study to compare the dose requirement of Oxytocin for management of uterine atony in patients receiving prophylactic Phenylephrine during Cesarean Delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044631
Enrollment
100
Registered
2022-08-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O746- Other complications of spinal andepidural anesthesia during labor and delivery

Interventions

Intervention1: Prophylactic Phenylephrine infusion: Patients will receive either 50 ml/hour of phenylephrine (Dose-0.5 �¼g/kg/min) in the intervention group intravenously,for 60-90 minutes Control I

Sponsors

College of Medicine and Sagore Dutta Hospital Kamarhati Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. single pregnancy at full-term (gestational age �37 weeks) b. American Society of Anesthesiologists Physical Status I and II c. aged between 20 and 35 years old undergoing caesarean section

Exclusion criteria

Exclusion criteria: a. obesity (body mass index, BMI >35 kg/m2), b. height ( 170 cm), c. active labor/ early labor d. diabetes mellitus or gestational diabetes e. hypertension or pre-eclampsia f. intrauterine growth restriction or fetal macrosomia g. placenta previa, placenta conglutination, placenta implantation h. significant co-existing maternal disease i. any absolute contraindications to spinal anesthesia such as local infection or bleeding disorders, and cases with a sensory plane block that did not reach T6 or higher.

Design outcomes

Primary

MeasureTime frame
1. mean total dose of oxytocin used during CD.Timepoint: 24 hours

Secondary

MeasureTime frame
1.proportion (%) of patients requiring a secondary uterotonic agent 2. estimated blood loss in the 24 h after surgery (EBL) 3. adverse effects during surgery (hypotension, bradycardia, nausea and vomiting, flushing, chest pain, or dyspnea). Timepoint: 24 hours

Countries

India

Contacts

Public ContactDr Nairita Mayur

College of Medicine & Sagore Dutta Hospital, Kolkata

nairitalive@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026